Dacliximab or daclizumab
- Level
- Commodity
- Parent
- 51202400
- Below
- 0
- Links · KBLI
- 8
Definition
UNSPSC 51202407This classification denotes a monoclonal antibody and immunosuppressant with the molecular formula C6394H9888N1696O2012S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CUJ2MVI71Y, more generally known as daclizumab. European Medicines Agency schedules daclizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06885MIG. The term DACLIZUMAB is an International Non-Proprietary Name or INN. Dacliximab or daclizumab bears US NLM identifiers UMLS ID C0663182 and NCI Concept Code C1569. Most nations, for tariff and trade purposes, schedule dacliximab or daclizumab under 30021002 and SITC 54163. SMILES: NONE.
Same parent
Under 51202400 · 21Activities that produce or sell this
KBLI · 8Inherited from family 51200000.
Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.